LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Will Pay Quarterly Dividend of $0.25

LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) declared a quarterly dividend on Tuesday, October 27th. Investors of record on Thursday, November 19th will be paid a dividend of $0.25 per share by the medical instruments supplier on Thursday, December 3rd. This represents a $1.00 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date is Thursday, November 19th.

LeMaitre Vascular has increased its dividend by an average of 0.2% per year over the last three years and has increased its dividend annually for the last 14 consecutive years. LeMaitre Vascular has a dividend payout ratio of 42.0% meaning its dividend is sufficiently covered by earnings. Research analysts expect LeMaitre Vascular to earn $3.15 per share next year, which means the company should continue to be able to cover its $1.00 annual dividend with an expected future payout ratio of 31.7%.

LeMaitre Vascular Trading Down 1.6%

Shares of LMAT stock opened at $77.01 on Tuesday. LeMaitre Vascular has a 12-month low of $76.60 and a 12-month high of $118.01. The company has a current ratio of 14.60, a quick ratio of 12.54 and a debt-to-equity ratio of 0.39. The firm’s 50 day moving average is $81.24 and its 200 day moving average is $93.91. The stock has a market capitalization of $1.76 billion, a P/E ratio of 28.00, a P/E/G ratio of 2.29 and a beta of 0.51.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.04). The company had revenue of $67.97 million for the quarter, compared to analysts’ expectations of $67.39 million. LeMaitre Vascular had a net margin of 23.51% and a return on equity of 15.33%. LeMaitre Vascular’s quarterly revenue was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.75 earnings per share. Research analysts expect that LeMaitre Vascular will post 2.83 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on the company. Citizens Jmp started coverage on LeMaitre Vascular in a report on Thursday, November 5th. They issued a “market outperform” rating and a $110.00 price objective for the company. Wells Fargo & Company lowered their target price on LeMaitre Vascular from $94.00 to $86.00 and set an “equal weight” rating on the stock in a report on Thursday, November 5th. Weiss Ratings cut LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 23rd. Seaport Research Partners set a $110.00 target price on LeMaitre Vascular in a research report on Thursday, November 5th. Finally, Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Three equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $108.25.

Read Our Latest Research Report on LeMaitre Vascular

LeMaitre Vascular Company Profile

(Get Free Report)

LeMaitre Vascular develops, manufactures and markets medical devices used primarily in the treatment of vascular disease. Its products support procedures performed by vascular surgeons and include vascular grafts, embolectomy catheters, carotid shunts, valvulotomes and other instruments used in vascular surgery. Founded in 1983 by vascular surgeon George LeMaitre, the company is headquartered in Burlington, Massachusetts. Its products are sold to hospitals and medical professionals around the world through a combination of direct sales and distributors.

See Also

Dividend History for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.